alfacalcidol 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
Vitamin D analogues/derivatives	130	41294-56-8

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: alfacalcidol 1alpha-Hydroxycholecalciferol alfarol alphacalcidol einsalpha alpha-calcidol 1-hydroxycholecalciferol	Molecular weight: 400.65 Formula: C27H44O2 CLOGP: 8.24 LIPINSKI: 1 HAC: 2 HDO: 2 TPSA: 40.46 ALOGS: -5.39 ROTB: 6

Molecule

Description

Molfile Inchi Smiles

Synonyms:

alfacalcidol
1alpha-Hydroxycholecalciferol
alfarol
alphacalcidol
einsalpha
alpha-calcidol
1-hydroxycholecalciferol

Molecular weight: 400.65
Formula: C27H44O2
CLOGP: 8.24
LIPINSKI: 1
HAC: 2
HDO: 2
TPSA: 40.46
ALOGS: -5.39
ROTB: 6

Drug dosage:

Dose	Unit	Route
1	mcg	O
1	mcg	P
10	mg	O

ADMET properties:

Property	Value	Reference
BDDCS (Biopharmaceutical Drug Disposition Classification System)	1	Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine)	8 %	Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose)	0.00 µM/kg/day	Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability)	71 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
CL (Clearance)	0.82 mL/min/kg	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	48.60 hours	Lombardo F, Berellini G, Obach RS

Approvals:

Date	Agency	Company	Orphan
Jan. 1, 1978	YEAR INTRODUCED

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Muscle spasticity	406.60	15.15	161	14305	17023	50573635
Respiratory disorder	349.89	15.15	173	14293	31014	50559644
Ear pain	338.55	15.15	164	14302	28119	50562539
Night sweats	332.01	15.15	171	14295	33403	50557255
Body temperature increased	316.75	15.15	162	14304	31179	50559479
Lower respiratory tract infection	154.83	15.15	162	14304	95039	50495619
Urticaria	150.36	15.15	185	14281	129376	50461282
Insomnia	128.08	15.15	200	14266	174665	50415993
Hypocalcaemia	127.38	15.15	85	14381	26731	50563927
Back pain	111.73	15.15	214	14252	219816	50370842
Abdominal pain upper	102.67	15.15	172	14294	159137	50431521
Sinusitis	94.12	15.15	172	14294	170386	50420272
Hypercalcaemia	89.73	15.15	65	14401	23287	50567371
Pruritus	89.60	15.15	228	14238	283340	50307318
Upper respiratory tract inflammation	87.99	15.15	31	14435	2358	50588300
Peripheral swelling	86.26	15.15	185	14281	205751	50384907
Osteonecrosis of jaw	82.77	15.15	71	14395	32455	50558203
Hepatic function abnormal	80.45	15.15	70	14396	32611	50558047
Drug ineffective	78.21	15.15	72	14394	819261	49771397
Renal impairment	78.05	15.15	102	14364	75559	50515099
Spinal compression fracture	77.20	15.15	47	14419	12609	50578049
Fatigue	71.30	15.15	59	14407	707542	49883116
Shunt stenosis	67.53	15.15	17	14449	398	50590260
Vomiting	62.13	15.15	278	14188	460480	50130178
Asthenia	57.69	15.15	211	14255	318831	50271827
Diarrhoea	54.15	15.15	319	14147	588157	50002501
Rash	52.34	15.15	255	14211	437216	50153442
Joint swelling	50.13	15.15	169	14297	245117	50345541
Drug intolerance	47.75	15.15	4	14462	219100	50371558
Drug hypersensitivity	42.18	15.15	10	14456	251000	50339658
Blood parathyroid hormone increased	41.64	15.15	19	14447	2835	50587823
Product dose omission issue	41.05	15.15	3	14463	183835	50406823
Incorrect route of product administration	38.10	15.15	36	14430	18630	50572028
Atypical femur fracture	37.21	15.15	21	14445	4895	50585763
Hyperuricaemia	35.44	15.15	20	14446	4660	50585998
Interstitial lung disease	34.93	15.15	58	14408	53118	50537540
Abdominal discomfort	33.82	15.15	12	14454	231629	50359029
Alopecia	33.62	15.15	14	14452	245033	50345625
Cardiac failure	32.52	15.15	69	14397	75971	50514687
Toxoplasmosis	32.50	15.15	13	14453	1404	50589254
Shunt occlusion	32.32	15.15	10	14456	506	50590152
Enteritis infectious	31.94	15.15	14	14452	1901	50588757
Cerebral infarction	31.92	15.15	35	14431	21569	50569089
Lymph node palpable	31.20	15.15	7	14459	98	50590560
Nausea	31.17	15.15	101	14365	705297	49885361
Iron deficiency anaemia	29.74	15.15	30	14436	16804	50573854
Arthropathy	29.19	15.15	5	14461	157901	50432757
Tetany	27.52	15.15	12	14454	1609	50589049
Large intestine polyp	27.22	15.15	20	14446	7312	50583346
Gastroenteritis	26.52	15.15	33	14433	23248	50567410
Treatment failure	26.24	15.15	4	14462	137633	50453025
Headache	25.88	15.15	239	14227	506296	50084362
Milk-alkali syndrome	25.65	15.15	9	14457	676	50589982
Osteomyelitis	24.37	15.15	31	14435	22322	50568336
Beta 2 microglobulin urine increased	24.11	15.15	5	14461	47	50590611
Glossodynia	22.87	15.15	3	14463	115566	50475092
Anaemia	22.49	15.15	136	14330	252320	50338338
Calciphylaxis	21.96	15.15	12	14454	2626	50588032
Haemodialysis complication	21.89	15.15	6	14460	197	50590461
Anxiety	21.51	15.15	12	14454	177594	50413064
Enterocolitis viral	21.49	15.15	6	14460	211	50590447
Rheumatoid arthritis	21.38	15.15	16	14450	202534	50388124
Oncocytoma	21.16	15.15	4	14462	22	50590636
Death	21.10	15.15	38	14428	325341	50265317
Toxicity to various agents	20.92	15.15	18	14448	212481	50378177
Nephrogenic anaemia	20.70	15.15	10	14456	1695	50588963
Periodontitis	20.27	15.15	12	14454	3057	50587601
Immunosuppressant drug level increased	20.22	15.15	12	14454	3070	50587588
Enterocolitis	20.17	15.15	16	14450	6551	50584107
Platelet count decreased	20.15	15.15	69	14397	100657	50490001
Pneumonia aspiration	19.27	15.15	33	14433	30971	50559687
Product monitoring error	18.76	15.15	11	14455	2753	50587905
Peripheral arterial occlusive disease	18.70	15.15	12	14454	3525	50587133
Immobilisation syndrome	18.64	15.15	5	14461	151	50590507
Infusion related reaction	18.41	15.15	13	14453	169544	50421114
Wound	18.17	15.15	4	14462	105790	50484868
Premature rupture of membranes	18.16	15.15	13	14453	4567	50586091
Neuropsychiatric lupus	18.07	15.15	5	14461	170	50590488
Pharyngitis	17.10	15.15	23	14443	17480	50573178
Blood albumin decreased	17.09	15.15	20	14446	13216	50577442
Precocious puberty	17.03	15.15	5	14461	211	50590447
Discomfort	16.89	15.15	5	14461	108375	50482283
Hypophosphataemia	16.73	15.15	16	14450	8398	50582260
Community acquired infection	16.66	15.15	3	14463	12	50590646
Musculoskeletal stiffness	16.56	15.15	8	14458	128473	50462185
Neurosis	16.37	15.15	5	14461	242	50590416
Cystitis	16.29	15.15	38	14428	44526	50546132
Colon cancer	16.29	15.15	16	14450	8675	50581983
Hungry bone syndrome	16.21	15.15	4	14462	86	50590572
Liver disorder	16.16	15.15	34	14432	37188	50553470
Colitis microscopic	16.10	15.15	14	14452	6506	50584152
Calculus urinary	16.03	15.15	7	14459	941	50589717
Retinal haemorrhage	15.90	15.15	12	14454	4569	50586089
Oesophageal mucosal tear	15.65	15.15	3	14463	18	50590640
Autoimmune pancytopenia	15.64	15.15	4	14462	100	50590558
Hepatic enzyme increased	15.62	15.15	10	14456	137370	50453288

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Shunt stenosis	120.68	18.04	28	6968	561	29566970
Hypocalcaemia	113.56	18.04	67	6929	20598	29546933
Shunt occlusion	79.85	18.04	21	6975	715	29566816
Oesophageal perforation	65.24	18.04	18	6978	737	29566794
Immunosuppressant drug level increased	59.93	18.04	27	6969	4738	29562793
Soft tissue mass	58.84	18.04	16	6980	620	29566911
Multimorbidity	56.22	18.04	15	6981	540	29566991
Osteonecrosis of jaw	47.94	18.04	36	6960	16474	29551057
Hepatic function abnormal	45.28	18.04	51	6945	39208	29528323
Transplant failure	41.78	18.04	18	6978	2838	29564693
Superinfection	40.82	18.04	16	6980	1985	29565546
Upper respiratory tract inflammation	40.41	18.04	15	6981	1605	29565926
Renal impairment	39.83	18.04	70	6926	81263	29486268
Oesophageal carcinoma	39.56	18.04	20	6976	4527	29563004
Procalcitonin abnormal	39.17	18.04	10	6986	302	29567229
Aplasia pure red cell	36.01	18.04	20	6976	5471	29562060
Myocardial ischaemia	35.89	18.04	30	6966	15998	29551533
Labelled drug-drug interaction medication error	34.16	18.04	26	6970	12133	29555398
Anti-erythropoietin antibody negative	32.67	18.04	8	6988	203	29567328
Neuromyopathy	32.63	18.04	11	6985	888	29566643
Inflammatory marker increased	31.52	18.04	16	6980	3651	29563880
Calciphylaxis	31.35	18.04	11	6985	1001	29566530
Encephalomalacia	30.46	18.04	10	6986	743	29566788
Hypercalcaemia	28.81	18.04	24	6972	12735	29554796
C-reactive protein increased	28.29	18.04	43	6953	44220	29523311
Drug ineffective	27.91	18.04	27	6969	363143	29204388
Lung consolidation	26.75	18.04	16	6980	5027	29562504
Retinopathy hypertensive	26.08	18.04	7	6989	258	29567273
Cardiomegaly	25.23	18.04	23	6973	13753	29553778
Device related sepsis	24.75	18.04	12	6984	2483	29565048
Drug level increased	24.41	18.04	26	6970	18761	29548770
PO2 decreased	24.02	18.04	10	6986	1449	29566082
Interstitial lung disease	23.60	18.04	46	6950	57672	29509859
Drug interaction	22.29	18.04	99	6897	197286	29370245
Cerebral infarction	21.78	18.04	28	6968	24647	29542884
Extraskeletal ossification	20.97	18.04	4	6992	29	29567502
Rales	20.96	18.04	16	6980	7494	29560037
Lymphocyte count increased	20.60	18.04	11	6985	2783	29564748
Fatigue	20.55	18.04	27	6969	316794	29250737
Immune thrombocytopenia	20.28	18.04	16	6980	7861	29559670
PCO2 decreased	19.86	18.04	9	6987	1599	29565932
Hepatosplenomegaly neonatal	19.82	18.04	4	6992	40	29567491
Bradycardia foetal	19.80	18.04	6	6990	343	29567188
Monocyte count increased	19.76	18.04	12	6984	3874	29563657
Myeloperoxidase deficiency	19.47	18.04	4	6992	44	29567487
Nail discolouration	18.43	18.04	7	6989	797	29566734
Hyperkalaemia	18.26	18.04	43	6953	61349	29506182
Acute kidney injury	18.23	18.04	116	6880	265151	29302380
Disseminated intravascular coagulation	18.14	18.04	23	6973	19957	29547574

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hypocalcaemia	207.32	12.98	139	19386	41614	64437593
Shunt stenosis	177.53	12.98	45	19480	1022	64478185
Muscle spasticity	154.62	12.98	83	19442	16586	64462621
Ear pain	127.89	12.98	85	19440	25051	64454156
Osteonecrosis of jaw	125.94	12.98	101	19424	39724	64439483
Upper respiratory tract inflammation	121.41	12.98	45	19480	3737	64475470
Respiratory disorder	117.21	12.98	93	19432	36018	64443189
Hepatic function abnormal	116.15	12.98	119	19406	64194	64415013
Night sweats	115.22	12.98	92	19433	35954	64443253
Hypercalcaemia	110.83	12.98	85	19440	31331	64447876
Shunt occlusion	106.55	12.98	31	19494	1196	64478011
Body temperature increased	103.38	12.98	87	19438	36579	64442628
Renal impairment	98.23	12.98	159	19366	134858	64344349
Drug ineffective	86.16	12.98	77	19448	840170	63639037
Spinal compression fracture	82.57	12.98	53	19472	14722	64464485
Fatigue	81.14	12.98	65	19460	748665	63730542
Oesophageal perforation	63.34	12.98	20	19505	1021	64478186
Blood parathyroid hormone increased	61.04	12.98	26	19499	3108	64476099
Lower respiratory tract infection	60.20	12.98	105	19420	94509	64384698
Interstitial lung disease	55.21	12.98	103	19422	97629	64381578
Aplasia pure red cell	51.59	12.98	30	19495	6984	64472223
Immunosuppressant drug level increased	50.63	12.98	30	19495	7229	64471978
Cerebral infarction	50.15	12.98	62	19463	40982	64438225
Soft tissue mass	49.29	12.98	16	19509	893	64478314
Multimorbidity	43.68	12.98	15	19510	997	64478210
Hyperuricaemia	41.34	12.98	30	19495	10161	64469046
Drug intolerance	39.82	12.98	5	19520	187987	64291220
Platelet count decreased	39.45	12.98	126	19399	167585	64311622
Urticaria	37.72	12.98	114	19411	147203	64332004
Insomnia	37.24	12.98	138	19387	197698	64281509
Procalcitonin abnormal	36.63	12.98	10	19515	305	64478902
Transplant failure	35.47	12.98	19	19506	3775	64475432
Product dose omission issue	35.04	12.98	8	19517	194739	64284468
Oesophageal carcinoma	34.13	12.98	20	19505	4723	64474484
Peripheral arterial occlusive disease	34.01	12.98	23	19502	6964	64472243
Anaemia	33.85	12.98	213	19312	378467	64100740
Drug hypersensitivity	33.55	12.98	15	19510	237800	64241407
Gastroenteritis	33.30	12.98	43	19482	29668	64449539
Cardiac failure	32.54	12.98	101	19424	132272	64346935
Diarrhoea	32.27	12.98	347	19178	722357	63756850
Calciphylaxis	32.13	12.98	17	19508	3295	64475912
Disseminated intravascular coagulation	31.94	12.98	44	19481	32304	64446903
Completed suicide	31.90	12.98	14	19511	224400	64254807
Large intestine polyp	31.12	12.98	26	19499	10811	64468396
Enteritis infectious	30.68	12.98	16	19509	3012	64476195
Superinfection	29.59	12.98	17	19508	3869	64475338
Tetany	29.48	12.98	14	19511	2158	64477049
Nausea	29.02	12.98	131	19394	785669	63693538
Back pain	28.39	12.98	150	19375	250021	64229186
Anti-erythropoietin antibody negative	28.11	12.98	8	19517	285	64478922
Labelled drug-drug interaction medication error	28.03	12.98	34	19491	22028	64457179
Lymph node palpable	28.00	12.98	7	19518	150	64479057
Weight increased	27.75	12.98	15	19510	213333	64265874
Hungry bone syndrome	27.53	12.98	7	19518	161	64479046
Atypical femur fracture	26.61	12.98	17	19508	4681	64474526
Incorrect route of product administration	26.55	12.98	34	19491	23264	64455943
Neuromyopathy	25.49	12.98	11	19514	1357	64477850
Toxoplasmosis	25.01	12.98	13	19512	2431	64476776
Hyperhidrosis	24.86	12.98	4	19521	124916	64354291
Encephalomalacia	24.44	12.98	10	19515	1081	64478126
Decreased appetite	24.34	12.98	157	19368	281132	64198075
Hypophosphataemia	24.33	12.98	26	19499	14694	64464513
Hyperphosphataemia	24.03	12.98	15	19510	3966	64475241
Beta 2 microglobulin urine increased	23.93	12.98	6	19519	130	64479077
Pruritus	23.83	12.98	169	19356	312231	64166976
Inflammatory marker increased	23.69	12.98	20	19505	8431	64470776
Iron deficiency anaemia	23.47	12.98	31	19494	21858	64457349
Periodontitis	23.43	12.98	15	19510	4144	64475063
Enterocolitis viral	23.17	12.98	7	19518	308	64478899
Liver disorder	22.68	12.98	50	19475	53301	64425906
Treatment failure	22.67	12.98	4	19521	116812	64362395
Pneumonia aspiration	22.38	12.98	53	19472	59218	64419989
Osteomyelitis	22.10	12.98	34	19491	27553	64451654
Myocardial ischaemia	22.01	12.98	31	19494	23220	64455987
Immobilisation syndrome	21.51	12.98	7	19518	394	64478813
Abdominal pain upper	21.26	12.98	107	19418	174923	64304284
Enterocolitis	21.24	12.98	22	19503	11996	64467211
Abdominal discomfort	20.69	12.98	15	19510	182307	64296900
Pharyngitis	20.47	12.98	27	19498	19012	64460195
Immune thrombocytopenia	20.42	12.98	24	19501	15042	64464165
Retinopathy hypertensive	20.42	12.98	7	19518	463	64478744
Milk-alkali syndrome	20.30	12.98	9	19516	1184	64478023
Oncocytoma	19.86	12.98	4	19521	30	64479177
Premature rupture of membranes	19.85	12.98	13	19512	3731	64475476
C-reactive protein increased	19.36	12.98	68	19457	94841	64384366
Haemodialysis complication	19.14	12.98	6	19519	299	64478908
Chronic gastritis	19.04	12.98	12	19513	3228	64475979
Anxiety	18.97	12.98	20	19505	202629	64276578
Nephrogenic anaemia	18.75	12.98	12	19513	3313	64475894
Sinusitis	18.28	12.98	90	19435	145838	64333369
Neuropsychiatric lupus	18.20	12.98	5	19520	156	64479051
Vomiting	18.13	12.98	250	19275	550867	63928340
Arthropathy	18.06	12.98	7	19518	120960	64358247
Nephrotic syndrome	17.79	12.98	18	19507	9549	64469658
Intentional overdose	17.63	12.98	3	19522	89941	64389266
Rash	17.59	12.98	214	19311	458335	64020872
Peritonitis	17.52	12.98	29	19496	24994	64454213
Death	17.44	12.98	81	19444	482624	63996583
Depression	17.26	12.98	18	19507	183273	64295934
Skin erosion	17.08	12.98	12	19513	3864	64475343
Lung consolidation	17.05	12.98	16	19509	7742	64471465
Infusion related reaction	16.82	12.98	15	19510	164452	64314755
Colon cancer	16.78	12.98	20	19505	12719	64466488
Therapeutic product effect decreased	16.69	12.98	7	19518	115344	64363863
Alopecia	15.91	12.98	16	19509	165674	64313533
PO2 decreased	15.82	12.98	10	19515	2703	64476504
Haemorrhage subcutaneous	15.81	12.98	12	19513	4349	64474858
Oesophageal mucosal tear	15.78	12.98	3	19522	16	64479191
Injection site pain	15.74	12.98	7	19518	111401	64367806
Pneumonia bacterial	15.67	12.98	21	19504	15014	64464193
Shunt aneurysm	15.62	12.98	3	19522	17	64479190
Hyperkalaemia	15.35	12.98	66	19459	101063	64378144
Protein urine present	15.12	12.98	16	19509	8940	64470267
Hypothyroidism	15.08	12.98	36	19489	40421	64438786
Precocious puberty	15.04	12.98	5	19520	301	64478906
Premature delivery	15.02	12.98	23	19502	18566	64460641
Idiopathic pulmonary fibrosis	14.99	12.98	11	19514	3789	64475418
Hypotension	14.92	12.98	62	19463	380912	64098295
Pemphigoid	14.87	12.98	19	19506	12967	64466240
Community acquired infection	14.51	12.98	3	19522	26	64479181
Syncope	14.26	12.98	16	19509	157619	64321588
Pneumonia	14.22	12.98	243	19282	559333	63919874
Pyelonephritis acute	14.09	12.98	12	19513	5122	64474085
Device related sepsis	14.04	12.98	12	19513	5143	64474064
Feeling abnormal	13.89	12.98	12	19513	133590	64345617
Myeloperoxidase deficiency	13.87	12.98	3	19522	33	64479174
Colitis microscopic	13.85	12.98	14	19511	7418	64471789
Neurosis	13.82	12.98	5	19520	387	64478820
Calculus urinary	13.81	12.98	8	19517	1849	64477358
Aortic dissection	13.63	12.98	10	19515	3442	64475765
Gastric cancer	13.53	12.98	13	19512	6480	64472727
Dermatophytosis of nail	13.51	12.98	4	19521	164	64479043
Concomitant disease aggravated	13.40	12.98	17	19508	11525	64467682
Sepsis	13.34	12.98	117	19408	230224	64248983
Stag horn calculus	13.33	12.98	4	19521	172	64479035
Marasmus	13.03	12.98	6	19519	862	64478345

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	A11CC03	ALIMENTARY TRACT AND METABOLISM VITAMINS VITAMIN A AND D, INCL. COMBINATIONS OF THE TWO Vitamin D and analogues
ATC	M05BB06	MUSCULO-SKELETAL SYSTEM DRUGS FOR TREATMENT OF BONE DISEASES DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION Bisphosphonates, combinations
MeSH PA	D050071	Bone Density Conservation Agents
CHEBI has role	CHEBI:50646	antiosteoporotic

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Renal osteodystrophy	indication	16726004	DOID:13068
Hypoparathyroidism	indication	36976004	DOID:11199
Hyperparathyroidism	indication	66999008	DOID:13543
Neonatal hypocalcemia	indication	268846006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	13.7	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Vitamin D3 receptor	Nuclear hormone receptor	P11473	VDR_HUMAN	AGONIST				WOMBAT-PK	KEGG DRUG
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN		Ki	6		DRUG MATRIX

External reference:

ID	Source
D01518	KEGG_DRUG
12062	RXNORM
C0044410	UMLSCUI
CHEBI:31186	CHEBI
M9B	PDB_CHEM_ID
CHEMBL1601669	ChEMBL_ID
DB01436	DRUGBANK_ID
C008088	MESH_SUPPLEMENTAL_RECORD_UI
5282181	PUBCHEM_CID
4489	INN_ID
URQ2517572	UNII
003501	NDDF
11984007	SNOMEDCT_US
329325000	SNOMEDCT_US

Pharmaceutical products:

None